Number of the records: 1
Innate immunity based cancer immunotherapy: B16-F10 murine melanoma model
- 1.
SYSNO ASEP 0472624 Document Type J - Journal Article R&D Document Type Journal Article Subsidiary J Článek ve WOS Title Innate immunity based cancer immunotherapy: B16-F10 murine melanoma model Author(s) Caisová, V. (CZ)
Vieru, A. (CZ)
Kumžáková, Z. (CZ)
Glaserová, S. (CZ)
Husniková, H. (CZ)
Vácová, N. (CZ)
Krejčová, G. (CZ)
Paďouková, L. (CZ)
Jochmanová, I. (SK)
Wolf, K. I. (US)
Chmelař, J. (CZ)
Kopecký, Jan (BC-A) RID
Ženka, J. (CZ)Number of authors 13 Article number 940 Source Title Bmc Cancer. - : BioMed Central
Roč. 16, č. 1 (2016)Number of pages 11 s. Publication form Online - E Language eng - English Country GB - United Kingdom Keywords cancer immunotherapy ; innate immunity ; melanoma ; neutrophils ; resiquimod ; mannan ; phagocytosis Subject RIV EC - Immunology Institutional support BC-A - RVO:60077344 UT WOS 000389382400003 EID SCOPUS 85003038894 DOI 10.1186/s12885-016-2982-x Annotation Background: Using killed microorganisms or their parts to stimulate immunity for cancer treatment dates back to the end of 19th century. Since then, it undergone considerable development. Our novel approach binds ligands to the tumor cell surface, which stimulates tumor phagocytosis. The therapeutic effect is further amplified by simultaneous application of agonists of Toll-like receptors. We searched for ligands that induce both a strong therapeutic effect and are safe for humans. Workplace Biology Centre (since 2006) Contact Dana Hypšová, eje@eje.cz, Tel.: 387 775 214 Year of Publishing 2017
Number of the records: 1